Drug Trial Radar · NCT04975997
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
939
Actual
Start
Jun 23, 2022
Primary completion
Nov 16, 2027
Study completion Jun 25, 2032
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Conditions
- Multiple Myeloma
Interventions
DexamethasoneDrug
Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle
DaratumumabDrug
Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle
BortezomibDrug
Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.
IberdomideDrug
Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle
IberdomideDrug
Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle
IberdomideDrug
Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle
DexamethasoneDrug
Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8
DaratumumabDrug
Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to approximately 5 years
- Minimal Residual Disease (MRD) negative Complete Response (CR) at any timeTime frame: Up to approximately 5 years
Locations
259 sites in 31 countries. Site status is shown where the registry gives one.
Local Institution - 035
Hot Springs, Arkansas
Local Institution - 641
Cerritos, California
Local Institution - 681
Fountain Valley, California
Local Institution - 047
Los Angeles, California
Local Institution - 684
Newport, California
Local Institution - 033
New Haven, Connecticut
Local Institution - 029
Fort Myers, Florida
Local Institution - 693
Ocala, Florida
Local Institution - 028
St. Petersburg, Florida
Local Institution - 045
Tamarac, Florida
Local Institution - 034
West Palm Beach, Florida
Local Institution - 685
Weston, Florida
Local Institution - 018
Atlanta, Georgia
Local Institution - 640
Elk Grove Village, Illinois
Local Institution - 697
Dyer, Indiana
Local Institution - 040
Louisville, Kentucky
Local Institution - 041
Alexandria, Louisiana
Local Institution - 682
Baton Rouge, Louisiana
Local Institution - 027
Baton Rouge, Louisiana
Local Institution - 698
Baltimore, Maryland
Local Institution - 014
Bethesda, Maryland
Local Institution - 688
Columbia, Maryland
Local Institution - 010
Boston, Massachusetts
Local Institution - 009
Worcester, Massachusetts
Local Institution - 645
Burnsville, Minnesota
Local Institution - 031
Kansas City, Missouri
Local Institution - 046
Billings, Montana
Local Institution - 015
Summit, New Jersey
Local Institution - 691
New York, New York
Local Institution - 039
Durham, North Carolina
Local Institution - 038
Cincinnati, Ohio
Local Institution - 037
Cleveland, Ohio
Local Institution - 008
Cleveland, Ohio
Local Institution - 036
Columbus, Ohio
Local Institution - 680
Tulsa, Oklahoma
Local Institution - 043
Portland, Oregon
Local Institution - 030
Chattanooga, Tennessee
Local Institution - 021
Nashville, Tennessee
Local Institution - 687
Austin, Texas
Local Institution - 695
Houston, Texas
Showing 40 of 259 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.